High-Cost Drugs: Impacts on the Medicaid Program

Matt Salo
Executive Director
The National Association of Medicaid Directors

April 9, 2015
National Association of Medicaid Directors (NAMD)

- NAMD created in 2011 to support the 56 state and territorial Medicaid Directors.
- Core functions include:
  - Develop consensus on critical issues and leverage their influence with respect to national policy debates;
  - Facilitate dialogue and peer to peer learning amongst the members; and
  - Provide best practices and technical assistance tailored to individual members and the challenges they face.
Medicaid & Rx Drugs: Background

• Outpatient prescription drugs are an optional Medicaid benefit, but all Medicaid programs cover them
  • Mandatory for Medicaid expansion population
• The Medicaid Drug Rebate program
  • Mandatory coverage of FDA-approved drugs in exchange for rebates from manufacturers
  • States are responsible for collecting rebates
  • Medicaid programs may impose clinical protocols and prior authorization on drugs
  • Medicaid programs **CANNOT** exclude coverage of drugs, unlike private insurers
Hepatitis C in 2014: A Shock to the System

• Late 2013, Gilead brings Sovaldi to market
• Priced at $1,000 a pill, no competition until late Q4 2014
• Combination of more effective treatment, large treatable population, and high pricing = significant upfront costs for payers
• Questionable value proposition in the long term for any one payer
Hepatitis C: Medicaid Programs React

• Significant Medicaid spending in Q1, Q2 2014 on hepatitis C
  • Some programs saw spending in these quarters outpace previous 2 years combined
• Used clinical protocols, prior authorization tools to ensure appropriate utilization
  • Fibrosis scores
  • Abstinence from substance use
  • Prescribing provider requirements
• Attempted to negotiate supplemental rebates, limited success until competitors entered market
A Sign of What’s to Come?

• Will the hepatitis C breakthrough pricing model apply to other specialty drug products in development?
• If so, how can payers adapt to a model which prioritizes upfront costs in exchange for perceived long-term value?
• The Medicaid program as currently structured does not have the tools to support this pricing model
  • Increases in the drug budget require hard choices in other program areas
• A new conversation about value must take place
21st Century Cures: Innovation at What Cost?

- Curative treatments are a universal good, but access must be safeguarded
- Patient safety under accelerated approval pathways requires flexibility in Medicaid coverage of new therapies
  - Current program requires coverage regardless of approval pathway
  - Concerns about Medicaid population’s unique characteristics under accelerated approvals
- Fiscal integrity of public programs, including Medicaid, must be considered
21st Century Cures: Innovation at What Cost?

• Extended exclusivity periods inhibit competitors’ entrance into the market
• Lack of competition drives up costs for all payers, particularly Medicaid
  • Medicaid programs utilize supplemental rebates to expand access to new therapies
  • Negotiating rebates is contingent on competitors in the market
• These dynamics must be considered in any legislation aimed at overhauling the drug approval process

National Association of Medicaid Directors